Loading the session
Loading the session
Loading instrument
$80.31
−0.43%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 4 Nov 2026, 15:01 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
The 3 Nov 2026 close of $80.66 was 17.4% above its 50-day average ($68.68) and 15.6% above its 200-day average ($69.80). It has closed above the 200-day for 9 sessions, since 22 Oct 2026. The 50-day average crossed below the 200-day on 7 Apr 2026, 146 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
1 month: +22.7% (SPY −2.6%, XLV +9.9%). 3 months: +14.8% (SPY −2.2%, XLV +13.5%). 1 year: +8.3% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: GEHC, SPY and XLV · as of 3 Nov 2026
19.4M shares were sold short at the 15 Oct 2026 settlement, 4.3% of the 452.1M shares outstanding; covering them would take 5.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
28 Oct 2026 volume of 9.6M shares was 2.6× the average of the 30 sessions before it (3.7M), as the price rose 6.6%. SPY traded 0.7× its own average that session.
Daily volume against a 30-session baseline · as of 28 Oct 2026
The 14-session relative strength index closed at 80.2 on 3 Nov 2026, its 5th session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 3 Nov 2026
Price return, split-adjusted
At the 3 Nov 2026 close
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
April 29, 2026
−13.16%April 4, 2025
−15.96%April 30, 2024
−14.28%